Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis ...

Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current ...

Sionna Therapeutics, Inc SION IPO will take place February, 07 on the NASDAQ exchange under the ticker SION. The company is ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

New Delhi: Pharmaceutical major Dr Reddy's has got approval from the Subject Expert Committee (SEC) functional under the ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is right ...